Intercept Pharmaceuticals, Inc.

Other

Giuliani S.p.a.

Tes Pharma S.r.l.

Gipharmex S.p.a.

Lehner Ag

G.d. Searle & Company

Fondazione Istituto Italiano Di Tecnologia

Fidia S.p.a.

Alma Mater Studiorum-universitá Di Bologna

Newron Pharmaceuticals S.p.a.

Istituto Europeo Di Oncologia S.r.l.

Consiglio Nazionale Delle Ricerche

Università Degli Studi Di Perugia

Pellicciari, Roberto

Roberto Pellicciari

Antimo Gioiello

Stefano Fiorucci

Aldo Roda

Mark Pruzanski

Flavio Moroni

Giuliano Frigerio

Adam Matthew Gilbert

Virginio Castagnola

Johan Auwerx

Françoise Perron-Sierra

Antonio Macchiarulo

E Giuliano Frigerio

Klaus Seedorf

Nadia Raffaelli

Eric Christian Hansen

Peter John Larkin

Francesca De Franco

Patricia Salvati

Joseph B Monahan

Florian Thaler

Massimo Ferrari

Luca Benatti

Elena Barbanti

Alexis A Cordi

Gabriel Galvin

Jose Antonio Ortega Martinez

Orietta Veneroni

Myoung Goo Kim

Pier Giuseppe Pelicci

Giuliano E Frigerio

Ronald D Lewis, Ii

Mathew Yanik

Marinella Roberti

Giuseppina Di Stefano

Viola Previtali

Saverio Minucci

Greta Bagnolini

Marcella Manerba

Domenico Milano

Andrea Cavalli

Antimo Gioello

Nicola Giacche

Paride Liscio

Thomas Hensel

Giangermano Giuliani

Benedetto Natalini

Maura Marinozzi

Thomas H Lanthorn

Bartjan Koning

Frederik Ronald Leusink

Marsha Pellegrino

Fabiola Moretti

Francesca Mancini

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.

Compounds and compositions for the treatment of tumors

The present application provides a compound of formula I: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R-R, m, n, p, andare as described herein. The present invention relates generally to FXR modulators and to methods of making and using said compounds.

Farnesoid X receptor modulators

The present disclosure discloses compounds capable of modulating the activity of α-amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NADbiosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase

The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.

TGR5 modulators and methods of use thereof

The application relates to compounds of formula A: or a salt, solvate, ester, tautomer, amino acid conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.

The present application provides Compound 1: or a pharmaceutically acceptable salt or amino acid conjugate thereof. The present invention relates to an FXR activator and to methods of making and using said compound.

3-desoxy derivative and pharmaceutical compositions thereof

The present disclosure discloses compounds capable of modulating the activity of &#x3b1;-amino-&#x3b2;-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NADbiosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

The present disclosure relates to methods and novel intermediates useful in the preparation of a compound of formula I  or pharmaceutically acceptable salt, hydrate, solvate or amino acid, sulfate or glucuronide conjugate, or prodrug thereof, comprising the step of reacting a compound of formula I-4 with a halogenating reagent to provide a compound of formula I-5a 

Methods and intermediates for the preparation of bile acid derivatives

The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R, R, R, R, R, and Rare as described herein. The present invention relates generally to selective FXR agonists and to methods of making and using them.

Farnesoid x receptor modulators

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

Treatment of fibrosis using FXR ligands

The invention relates to compounds of formula (I): wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.

Steroids as agonists for FXR

Growing community of inventors

Perugia, Italy

Roberto Pellicciari